文献速递糖尿病肥胖与代谢综合征

每周一次IcoSema对比每周一次司美格鲁肽治疗成人2型糖尿病:COMBINE 2随机临床试验

Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.
PubMed 文献 · Diabetologia · 2025-01-17

COMBINE 2是一项52周、随机、多中心、开放标签、平行组、IIIa期试验,在13个国家/地区121个中心纳入683例GLP-1受体激动剂治疗控制不佳的2型糖尿病患者,1:1随机接受每周一次IcoSema或司美格鲁肽1.0 mg。IcoSema在HbA1c降幅上优于司美格鲁肽1.0 mg,临床显著或严重低血糖发生率及胃肠道不良事件频率相似,但体重变化在司美格鲁肽1.0 mg组更有利。

要点

  • IcoSema组HbA1c降幅优于司美格鲁肽1.0 mg组,估计治疗差异为-4.85 mmol/mol(p<0.0001)。
  • 两组临床显著或严重低血糖发生率无统计学显著差异(率比1.20,95%CI 0.53, 2.69;p=0.66)。
  • 体重变化在司美格鲁肽1.0 mg组更有利:IcoSema组+0.84 kg vs 司美格鲁肽组-3.70 kg(p<0.0001)。

核心结论

  • 在GLP-1受体激动剂治疗控制不佳的2型糖尿病患者中,换用每周一次IcoSema较每周一次司美格鲁肽1.0 mg在HbA1c降幅上显示优效性,临床显著或严重低血糖发生率及胃肠道不良事件频率相似。
  • 体重从基线至第52周的变化在司美格鲁肽1.0 mg组更有利,组间差异有统计学意义。

研究设计与样本

  • 52周、随机、多中心、开放标签、平行组、IIIa期试验,在13个国家/地区121个中心开展。
  • 纳入HbA1c 53.0-85.8 mmol/mol(7.0-10.0%)且接受GLP-1受体激动剂治疗(联用或不联用其他口服降糖药)的成人2型糖尿病患者,1:1随机分配至每周一次IcoSema或每周一次司美格鲁肽1.0 mg。
  • 共683例参与者随机分组:IcoSema组n=342,司美格鲁肽1.0 mg组n=341。
  • 主要终点为基线至第52周HbA1c变化,评估IcoSema对司美格鲁肽1.0 mg的优效性。

主要发现

  • 基线至第52周HbA1c平均变化:IcoSema组-14.7 mmol/mol(-1.35%-points),司美格鲁肽组-9.88 mmol/mol(-0.90%-points);估计治疗差异-4.85(95%CI -6.13, -3.57)mmol/mol(-0.44 [95%CI -0.56, -0.33]%-points),p<0.0001。
  • 基线至第52周空腹血糖估计平均变化:IcoSema组-2.48 mmol/l vs 司美格鲁肽组-1.43 mmol/l;估计治疗差异-1.05(95%CI -1.36, -0.75)mmol,p<0.0001。
  • 基线至第52周体重平均变化:IcoSema组+0.84 kg vs 司美格鲁肽组-3.70 kg;估计治疗差异4.54 kg(95%CI 3.84, 5.23),p<0.0001。
  • 临床显著(2级;<3.0 mmol/l)或严重(3级;伴严重认知障碍需外部协助恢复)低血糖合并发生率:IcoSema组0.042次/人年暴露 vs 司美格鲁肽组0.036次/人年暴露;估计率比1.20(95%CI 0.53, 2.69),p=0.66,无统计学显著差异。
  • 胃肠道不良事件发生率:IcoSema组31.4%,司美格鲁肽组34.4%,两组相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: COMBINE 2 assessed the efficacy and safety of once-weekly IcoSema (a combination therapy of basal insulin icodec and semaglutide) vs once-weekly semaglutide (a glucagon-like peptide-1 analogue) 1.0 mg in individuals with type 2 diabetes inadequately managed with GLP-1 receptor agonist (GLP-1 RA) therapy, with or without additional oral glucose-lowering medications. METHODS: This 52 week, randomised, multicentre, open-label, parallel group, Phase IIIa trial was conducted across 121 sites in 13 countries/regions. Adults with type 2 diabetes (HbA1c 53.0-85.8 mmol/mol [7.0-10.0%]) receiving GLP-1 RA therapy with or without additional oral glucose-lowering medications were randomly assigned 1:1 to once-weekly IcoSema or once-weekly semaglutide 1.0 mg. The primary endpoint was change in HbA1c from baseline to week 52; superiority of IcoSema to semaglutide 1.0 mg was assessed. Secondary endpoints included change in fasting plasma glucose and body weight (baseline to week 52), and combined clinically significant (level 2; <3.0 mmol/l) or severe (level 3; associated with severe cognitive impairment requiring external assistance for recovery) hypoglycaemia (baseline to week 57). RESULTS: Overall, 683 participants were randomised using a Randomisation and Trial Supply Management system to IcoSema (n=342) or semaglutide 1.0 mg (n=341). Mean ± SD baseline characteristics were as follows: HbA1c 64.0±8.2 mmol/mol (8.0±0.7%); diabetes duration 12.6±6.9 years; and BMI 31.1±4.7 kg/m2. From baseline to week 52, mean change in HbA1c was -14.7 mmol/mol (-1.35%-points) in the IcoSema group and -9.88 mmol/mol (-0.90%-points) in the semaglutide group; the estimated treatment difference (ETD) was -4.85 (95% CI -6.13, -3.57) mmol/mol (-0.44 [95% CI -0.56, -0.33]%-points), confirming superiority of IcoSema to semaglutide (p<0.0001). The estimated mean change in fasting plasma glucose from baseline to week 52 was statistically significantly reduced with IcoSema vs semaglutide (-2.48 mmol/l vs -1.43 mmol/l, respectively; ETD -1.05 [95% CI -1.36, -0.75] mmol; p<0.0001). Mean change in body weight from baseline to week 52 was statistically significantly different between groups: +0.84 kg for IcoSema vs -3.70 kg for semaglutide (ETD 4.54 kg [95% CI 3.84, 5.23]; p<0.0001). There was no statistically significant difference in the rate of combined clinically significant or severe hypoglycaemia between IcoSema and semaglutide (0.042 vs 0.036 episodes per person-year of exposure; estimated rate ratio 1.20 [95% CI 0.53, 2.69]; p=0.66). The proportion of participants experiencing gastrointestinal adverse events was similar between treatment groups (IcoSema 31.4%; semaglutide 34.4%). CONCLUSIONS/INTERPRETATION: In people living with type 2 diabetes inadequately managed with GLP-1 RA therapy, with or without additional oral glucose-lowering medications, switching to once-weekly IcoSema in comparison with once-weekly semaglutide 1.0 mg demonstrated superiority in HbA1c reduction, similar rates of clinically significant or severe hypoglycaemia, and similar frequency of gastrointestinal adverse events. However, weight change from baseline to week 52 was statistically significantly in favour of semaglutide 1.0 mg. TRIAL REGISTRATION: ClinicalTrials.gov NCT05259033 FUNDING: This trial was funded by Novo Nordisk.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Lingvay I, Benamar M, Chen L, et al. Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial. Diabetologia. 2025. PMID: 39820580. doi:10.1007/s00125-024-06348-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。